4-(4-(2-Amino-2-methylpropyl)phenoxy)benzamide | 189119-38-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-(2-Amino-2-methylpropyl)phenoxy)benzamide
• 英文别名: 4-[4-(2-amino-2-methylpropyl)phenoxy]benzamide
• CAS: 189119-38-8
• 化学式: C₁₇H₂₀N₂O₂
• 分子量: 284.358
• InChiKey: CGIGDATUVOVBDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  78.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-(2-Amino-2-methylpropyl)phenoxy)benzamide 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 4-(4-{2-[(R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-2-methyl-propyl}-phenoxy)-benzamide
  参考文献：
  名称：

  The Application of High-Throughput Synthesis And Purification To The Preparation Of Ethanolamines

  摘要：

  A 48 compound library of structurally diverse ethanolamines was prepared using a parallel synthesis approach. The synthetic paradigm employed a solution phase epoxide-opening reaction followed by rapid purification by ion exchange chromatography to yield products with near-analytical purity. An array of epoxides and primary amines, arranged in an 8x6 matrix, were reacted in the presence of an in situ silylating agent to form 48 individual compounds with an average yield of 75% and an average purity of 92.3%. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(97)01421-4
• 作为产物：
  描述：

  4-(4-(2-amino-2-methylpropyl)phenoxy)benzonitrile 在 双氧水 、 potassium carbonate 作用下， 以 水 、 二甲基亚砜 为溶剂， 以55.0 g (97%)的产率得到4-(4-(2-Amino-2-methylpropyl)phenoxy)benzamide
  参考文献：
  名称：

  Selective beta3 adrenergic agonists

  摘要：

  本发明属于医学领域，特别是在治疗2型糖尿病和肥胖方面。更具体地说，本发明涉及对选择性β3肾上腺素能受体激动剂在治疗2型糖尿病和肥胖方面的应用。该发明提供了化合物和治疗2型糖尿病的方法，包括向需要的哺乳动物施用具有I和II式的化合物。

  公开号：

  EP0764640A1

文献信息

• Selective beta3 adrenergic agonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0764640A1

  公开（公告）日：1997-03-26

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II:

  本发明属于医学领域，特别是在治疗2型糖尿病和肥胖方面。更具体地说，本发明涉及对选择性β3肾上腺素能受体激动剂在治疗2型糖尿病和肥胖方面的应用。该发明提供了化合物和治疗2型糖尿病的方法，包括向需要的哺乳动物施用具有I和II式的化合物。
• Selective .beta.3 adrenergic agonists
  申请人：Eli Lilly and Company

  公开号：US06046227A1

  公开（公告）日：2000-04-04

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta..sub.3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I:

  本发明属于医学领域，特别是在治疗2型糖尿病和肥胖方面。更具体地说，本发明涉及选择性β3受体激动剂，用于治疗2型糖尿病和肥胖。该发明提供了一种化合物和治疗2型糖尿病和肥胖的方法，包括向需要的哺乳动物施用Formula I的化合物。
• Selective B3 adrenergic agonists
  申请人：——

  公开号：US20020165234A1

  公开（公告）日：2002-11-07

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr; 3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I: 1

  本发明属于医学领域，特别是用于治疗2型糖尿病和肥胖症。更具体地说，本发明涉及选择性β3受体激动剂，用于治疗2型糖尿病和肥胖症。本发明提供了化合物和治疗2型糖尿病和肥胖症的方法，包括向需要此类化合物的哺乳动物施用式I的化合物：1
• Selective &bgr;3 adrenergic agonists
  申请人：Eli Lilly and Company

  公开号：US06413991B1

  公开（公告）日：2002-07-02

  Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.

  本文披露了由以下结构式表示的选择性β3肾上腺素能激动剂：上述结构式中的变量在说明书中有定义。还披露了使用这些化合物在需要此类治疗的患者中激活β3肾上腺素能受体的方法，例如需要治疗肥胖症或2型糖尿病的患者。
• Selective .beta.-3 adrenergic agonists
  申请人：Eli Lilly and Company

  公开号：US05840738A1

  公开（公告）日：1998-11-24

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II: ##STR1##

  本发明属于医学领域，特别是在治疗2型糖尿病和肥胖方面。更具体地说，本发明涉及选择性β3肾上腺素受体激动剂，用于治疗2型糖尿病和肥胖。该发明提供了化合物和方法，用于治疗2型糖尿病，包括向需要的哺乳动物给予公式I和II的化合物：##STR1##